Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
Romiplostim was effective, safe, and well-tolerated over 6–12 months of continuous treatment in Phase 3 trials in patients with immune thrombocytopenia (ITP). This report describes up to 5 years of weekly treatment with romiplostim in 292 adult ITP patients in a long-term, single-arm, open-label stu...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2015-01-01
|
Series: | Onkogematologiâ |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/123 |